Patent Struggles Could Determine Japanese iPS Cell Work
This article was originally published in PharmAsia News
Executive Summary
The future of Japanese research and development of induced pluripotent stem cells could be determined by a possible patent competition. Bayer Yakuhin, the Japanese subsidiary of German's Bayer AG, says its researchers created iPS cells from human cells before a Kyoto University team, which announced its "breakthrough" work last November. In addition to Japanese researchers, the University of Wisconsin also has claimed success in creating iPS cells from human cells at the same time as the Kyoto University team. (Click here for more - a subscription may be required